OBaris has developed the OctoPatch®, a small, needle-free suction patch that applies negative pressure to the buccal mucosa and, with natural permeation enhancers, temporarily disrupts the barrier to deliver drugs to the bloodstream. The patch is a few millimeters in diameter, is self-applied to the inner cheek, and remains in place only briefly before removal. OBaris is targeting the therapeutic peptides market (approx. CHF 40 billion in 2023) with an initial focus on metabolic diseases such as diabetes, obesity, and osteoporosis. The company aims to partner with leading pharmaceutical firms to broaden patient access. The team includes CEO Nevena Paunoviç, CSO David Klein Cerrejon, Prof. Jean-Christophe Leroux, and Prof. Zhi Luo (advisory board). Operational plans highlighted in the articles include regulatory strategy validation, initiating an FDA meeting, and scaling up manufacturing.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2024